Plus Therapeutics
- Market Capitalization$7.4 M2022-05-13
OverviewSuggest Edit
Plus Therapeutics (formerly known as Cytori Therapeutics) is a pharmaceutical company focused on the discovery, development, and manufacturing of treatments for patients battling cancer and other life-threatening diseases. The company delivers a range of drugs using liposomal encapsulation technology.
| Type | Public | |
| Founded | 1996 | |
| HQ | Austin, TX, US | Map |
| Website | plustherapeutics.com | |
| Employee Ratings |
Recent NewsAll News
- Plus Therapeutics Reports First Quarter 2022 Financial Results and Business Highlights
- Plus Therapeutics Announces Oral Presentation at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2022 Annual Meeting
- Plus Therapeutics Announces Poster Presentation at the American Association for Cancer Research (AACR) Annual Meeting
- Plus Therapeutics and Medidata Announce Expanded Clinical Trial Partnership
Key People/Management at Plus Therapeutics
Marc Hedrick
President and CEO
Andrew Sims
Vice President and Chief Financial Officer
Cheri Rice
Vice President, Product Development
Norman Lafrance
Chief Medical Officer and Senior Vice President
Russ Havranek
Vice President, Corporate Strategy and New Product Planning
Richard Hawkins
Chairman
Plus Therapeutics Office Locations
Plus Therapeutics has offices in Austin and San Antonio
Austin, TX, US (HQ)
4200 Marathon Blvd #200
San Antonio, TX, US
12500 Network Blvd
Plus Therapeutics Financials and Metrics
Plus Therapeutics Revenue
Plus Therapeutics's revenue was reported to be $7 m in FY, 2019 which is a 90.6% increase from the previous period.
| USD | |
|---|---|
Net income (Q1, 2021) | (2.7m) |
EBIT (Q1, 2021) | (2.5m) |
Market capitalization (13-May-2022) | 7.4m |
Closing stock price (13-May-2022) | 0.5 |
Cash (31-Mar-2021) | 14.4m |
EV | (517.6k) |
Plus Therapeutics's current market capitalization is $7.4 m.
Annual
Annual
Quarterly
| USD | Q1, 2018 | Q2, 2018 | Q3, 2018 | Q1, 2019 | Q2, 2019 | Q3, 2019 | Q1, 2020 | Q2, 2020 | Q3, 2020 | Q1, 2021 |
|---|---|---|---|---|---|---|---|---|---|---|
Cash | 5.9m | 3.1m | 6.8m | 3.9m | 4.5m | 16.8m | 16.1m | 9.3m | 7.6m | 14.4m |
Accounts Receivable | 769.0k | 399.0k | 440.0k | 455.0k | 80.0k | 4.8m | 978.0k | 951.0k | ||
Inventories | 3.2m | 3.0m | 2.8m | 3.0m | 107.0k | 107.0k | 107.0k | 107.0k | 107.0k | |
Current Assets | 10.7m | 7.4m | 10.8m | 8.5m | 5.3m | 22.3m | 17.7m | 10.8m | 8.6m | 15.4m |
Annual
Quarterly
| USD | Q1, 2018 | Q2, 2018 | Q3, 2018 | Q1, 2019 | Q2, 2019 | Q3, 2019 | Q1, 2020 | Q2, 2020 | Q3, 2020 | Q1, 2021 |
|---|---|---|---|---|---|---|---|---|---|---|
Net Income | (4.4m) | (8.1m) | (10.4m) | (3.1m) | (12.3m) | (11.8m) | (1.1m) | (2.9m) | (4.7m) | (2.7m) |
Depreciation and Amortization | 497.0k | 975.0k | 1.5m | 443.0k | 617.0k | 778.0k | 94.0k | 188.0k | 273.0k | 88.0k |
Inventories | 141.0k | 371.0k | 615.0k | 16.0k | 235.0k | 274.0k | ||||
Accounts Payable | (556.0k) | (1.2m) | (1.3m) | (405.0k) | (94.0k) | (95.0k) | 410.0k | 371.0k | (1.6m) | (461.0k) |
| USD | FY, 2017 |
|---|---|
Revenue/Employee | 173.3k |
Debt/Equity | 1 x |
Debt/Assets | 0.4 x |
Financial Leverage | 2.4 x |
Plus Therapeutics Cybersecurity Score
Plus Therapeutics Online and Social Media Presence
320 Twitter followers
Plus Therapeutics has 320 Twitter Followers. The number of followers has increased 0.8% month over month and increased 4.4% quarter over quarter
Plus Therapeutics's Trends
Twitter Engagement Stats for @plustxinc
186
Tweets
1.5k
Following
320
Followers
3
Tweets last 30 days
2
Avg. likes per Tweet
100%
Tweets with engagement
Plus Therapeutics News and Updates
April 21, 2022
Plus Therapeutics Reports First Quarter 2022 Financial Results and Business Highlights
First patient dosed in ReSPECT-LM Phase 1/2a dose escalation trial of 186RNL for leptomeningeal metastases
April 19, 2022
Plus Therapeutics Announces Oral Presentation at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2022 Annual Meeting
AUSTIN, Texas, April 19, 2022 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for rare and difficult-to-treat cancers, today announced that it will discuss new data in an oral pres…
April 08, 2022
Plus Therapeutics Announces Poster Presentation at the American Association for Cancer Research (AACR) Annual Meeting
AUSTIN, Texas, April 08, 2022 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for rare and difficult-to-treat cancers, today announced that the company will present a poster at the…
April 05, 2022
Plus Therapeutics and Medidata Announce Expanded Clinical Trial Partnership
Companies collaborate to design innovative registrational trial of 186RNL for recurrent glioblastoma
March 23, 2022
Plus Therapeutics to Participate in the 2022 Virtual Growth Conference Presented by Maxim Group LLC and Hosted by M-Vest
AUSTIN, Texas, March 23, 2022 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV), a U.S. clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for rare and difficult-to-treat cancers, announced today that Marc Hedrick, M.D., President and Chief Executive O…
March 22, 2022
Plus Therapeutics Announces First Patient Dosed in Phase 1/2a Dose Escalation Trial of 186RNL Radiotherapeutic for Leptomeningeal Metastases
ReSPECT-LM trial to evaluate safety/tolerability and identify MTD/MFD in three cohorts
Plus Therapeutics Frequently Asked Questions
When was Plus Therapeutics founded?
Plus Therapeutics was founded in 1996.
Who are Plus Therapeutics key executives?
Plus Therapeutics's key executives are Marc Hedrick, Andrew Sims and Cheri Rice.
How many employees does Plus Therapeutics have?
Plus Therapeutics has 12 employees.
Who are Plus Therapeutics competitors?
Competitors of Plus Therapeutics include Praedicare Labs, Allogene Therapeutics and AVEO Pharmaceuticals.
Where is Plus Therapeutics headquarters?
Plus Therapeutics headquarters is located at 4200 Marathon Blvd #200, Austin.
Where are Plus Therapeutics offices?
Plus Therapeutics has offices in Austin and San Antonio.
How many offices does Plus Therapeutics have?
Plus Therapeutics has 2 offices.
Learn about Craft real-time company insights
Receive alerts for 300+ data fields across thousands of companies